Research & Presentations

Research

1.     A Clinical Trial Report of Autologous Bone Marrow derived Mesenchymal Stem Cell Transplantation in Patients with Spinal Cord Injury

2.    Evaluation of Immune Response to Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

3.     Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

4.     Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

5.     Allogeneic umbilical cord blood mononuclear cell therapy for spinal cord injury – a retrospective cohort study.

  • Our recent research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance; and presented at the American Academy of Orthopedic Surgeons Annual Meeting (New Orleans, LA, 2018), Adult Stem Cells and Regenerative Medicine Conference, The New York Academy of Sciences (NY, 2019), 7th Annual German Stem Cell Network Conference (Germany, Berlin, 2019). 
  • Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.
  • Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders, and other medical conditions.
  • The Food and Drug Administration (FDA) has given us the approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. The study is registered at the ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT03735277).

Presentations

 

  • • “Retrospective Chart Review Study of Human Adipose Tissue Derived Mesenchymal Stem Cell Therapy in Subjects with Musculoskeletal Disorders”. AAOS Annual Meeting, March 6-10, New Orleans, Louisiana, 2018. 
    • “Mesenchymal stem cells in clinical applications”. 6th International Conference on Tissue Engineering and Regenerative Medicine, San Francisco, USA, August 23-24,
    2017 
     March 5th, 2018 – March 10th, 2018;   NOLA AAOS
    • March 20- 22, 2017: 8th World Congress on Cell Science & Stem Cell Research, Orlando FL Dr Brian Mehling will be a speaker
  • http://stemcell.conferenceseries.com/
  • “Analysis of outcomes following mesenchymal stem cell therapy in subjects with musculoskeletal conditions”. Global Congress on Tissue Engineering, Regenerative & Precision Medicine. San Antonio, USA, December 01-02, 2016.
  • “Stem cell therapy for musculoskeletal conditions”. BIT’s 7th World Gene Convention – 2016, Shanghai, China, November 3-5, 2016.
  • “Analysis of outcomes following mesenchymal stem cell therapy in subjects with musculoskeletal conditions”. Cancer Immunotherapy & Biofluid Biopsies 2016. Boston, USA, Nov 1-2, 2016.
  • “Clinical applications of mesenchymal stem cells”. First Inter-American stem cell conference and fourth international symposium on cellular therapies and regenerative medicine. Havana, Cuba, October 13-15, 2016.
  • “Clinical Applications pf Mesenchymal Stem Cells”. Tissue Engineering and Regenerative Medicine. Berlin, Germany, Sept. 12-14, 2016.
  • “Stem Cell Therapy for Arthritis and Joint Injuries”. 7th Annual Conference on Stem Cell and Regenerative Medicine. Manchester, UK, August 4-5, 2016.
  • “Stem Cell Therapy in Regenerative Medicine”. 2nd European Congress of Hockey Medicine (II. ECHM), Bratislava, Slovakia, June 2-4, 2016.
  • “Stem Cell Therapy for Arthritis and Joint Injuries”. Musculoskeletal Disease and Regeneration, Chicago, IL, USA, May 5-6, 2016.
  • “Stem Cell Commercialization”. Annual meeting of IsraStem and ISCS (Israel Stem Cell Society), Tel Aviv, Israel, April 5-6, 2016.
  • “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation and Aging”. XXXIV. Cervenansky days, National Meeting of Slovak Orthopaedic and Traumatologic Society. Bratislava, Slovakia, March 10-11, 2016.
  • “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation and Aging”. 6th World Conference on Cell & Stem Cell Research. Philadelphia, PA, USA, February 29-March 2, 2016.
  • “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation and Aging”. 4th International Conference on Tissue Science and Regenerative Medicine. Rome, Italy, July 27-29, 2015.
  • “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation and Aging”. 17th International Conference on Tissue Engineering and Regenerative Medicine. Paris, France, July 20 – 21, 2015.
  • “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation and Aging”. XIV Slovak Geriatrics Congress. Strbske, Slovakia, April 15-17, 2015.
  • “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation”. Orthopaedic Research and Innovation Symposium. Wright State University, April 6, 2015.
  • “High Potency Stem Cell Treatments and Health Travel”. International Medical Travel Exhibition and Conference. United Arab Emirates, Dubai, March 5-6, 2014.
  • “Stem Cell Therapy for Spinal Cord Injury: A Retrospective Chart Review”. Wright State University Boonshoft School of Medicine Central Research Forum, October 16, 2014.
  • “Hematopoietic Stem Cells and Clinical Application”. Taishen Academic Forum, Hematopoietic Stem Cells and Leukemia. Weifang, Shangdong, China, 2013.